Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2014-12-17 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 129.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of securities held before and after the change, the nature of the transaction, and dates. This matches the definition of a Director's Dealing report, which involves personal share transactions by company directors. The document length is short and focused solely on this transaction, with no financial statements or broader company information. Therefore, it fits the 'Director's Dealing' category (DIRS).
2014-12-17 English
Appendix 3B 9 pages 355.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically ordinary shares and employee options, by Mayne Pharma Group Limited. It includes detailed information about the class, number, terms, issue price, purpose, and quotation of the securities. The document references ASX (Australian Securities Exchange) rules and compliance, indicating it is a formal announcement of a capital raising or share issue event. There are no financial statements, management discussion, or audit information present. The content aligns with announcements about new share issues or capital changes rather than a full financial report or other categories. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (12,712 characters) and detailed content confirm it is not a brief announcement or a report publication notice but a substantive filing about share issuance.
2014-12-04 English
Change of Director's Interest Notice 2 pages 127.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about changes in a director's relevant interests in securities, including the number of shares held before and after the change, acquisition details, and compliance with ASX listing rules. It specifically reports personal share transactions by a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 4022 characters, which is consistent with a detailed notice rather than a brief announcement. Therefore, the correct classification is DIRS.
2014-12-04 English
Change in substantial holding from WBC 11 pages 352.6KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' and is a 'Notice of change of interests of substantial holder' under the Corporations Act 2001 Section 671B. It details changes in voting power and relevant interests of a substantial holder (Westpac Banking Corporation and associated entities) in Mayne Pharma Group Limited. The content includes transaction history, changes in shareholdings, and relevant legal references. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document is lengthy (15,000 characters) and contains detailed data on share transactions and holdings, confirming it is not a brief announcement or a report publication notice. Therefore, the correct classification is MRQ with high confidence.
2014-11-30 English
Change in substantial holding from BTT 12 pages 175.9KB
Major Shareholding Notification Classification · 95% confidence The document is a Notice of Change of Interests of Substantial Holder filed under section 671B of the Corporations Act 2001 (Cth). It includes detailed information about changes in voting power, relevant interests, and transactions in shares by substantial holders and their associates. The document references Form 604, which is a regulatory filing used to notify changes in substantial shareholdings. It does not contain financial statements, management discussion, or earnings data. It is a regulatory announcement about shareholding changes, not a financial report or management report. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is substantial and contains detailed transaction history, supporting this classification with high confidence.
2014-11-30 English
2014 AGM Chairman's Speech 4 pages 239.6KB
AGM Information Classification · 95% confidence The document is an ASX announcement titled 'ANNUAL GENERAL MEETING' and contains the Chairman's address and business updates presented at the 2014 Mayne Pharma Annual General Meeting. It includes introductions of board members, a summary of financial performance, operational highlights, strategic priorities, and a business update by the CEO. The content is typical of materials shared during an AGM, including a Chairman's report and business overview, but does not contain detailed financial statements or formal voting results. The document length is over 11,000 characters, indicating it is a full AGM presentation rather than a brief announcement. Therefore, the document fits the category of AGM Information (AGM-R).
2014-11-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.